Uphill road for Cubist CVRs

Merck taking over Trius, Optimer CVRs, but neither looks likely to pay out

When Merck & Co. Inc. (NYSE:MRK) acquires Cubist Pharmaceuticals Inc. (NASDAQ:CBST), the pharma will take over the contingent value rights the infectious disease company owes the former shareholders of Optimer Pharmaceuticals Inc. and Trius Therapeutics Inc. Based on existing and projected sales of the antibiotics tied to the two CVRs, Merck will

Read the full 522 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE